Celgene Corporation CELG was added to Bank of America's US 1 List Monday morning, reflecting strong annual revenue and EPS growth.
The firm expects continued strong Revlimid growth momentum and a likely patent settlement, which would remove an overhang. Shares are Buy rated with a $112 price target. This is on the heels of a solid earnings report last week.
Shares of Celgene have moved from $84 on October 16 to all-time highs of $105.25 at time of publication, a 25 percent move.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.